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Aluminum enhances inflammation and decreases
mucosal healing in experimental colitis in mice
GPineton de Chambrun1,2,3,4,12, M Body-Malapel1,2,3,12, I Frey-Wagner5,MDjouina1,2,3, F Deknuydt6,7,8,
K Atrott5, N Esquerre1,2,3, F Altare6,7,8, C Neut1,2,3,9, MC Arrieta10, T-D Kanneganti11, G Rogler5,
J-F Colombel1,2,3,4, A Cortot1,2,3,4, P Desreumaux1,2,3,4 and C Vignal1,2,3
The increasing incidence of inflammatory bowel diseases (IBDs) in developing countries has highlighted the critical role
of environmental pollutants as causative factors in their pathophysiology. Despite its ubiquity and immune toxicity, the
impact of aluminum in the gut is not known. This study aimed to evaluate the effects of environmentally relevant
intoxicationwith aluminum inmurinemodels of colitis and to explore the underlyingmechanisms. Oral administration of
aluminum worsened intestinal inflammation in mice with 2,4,6-trinitrobenzene sulfonic acid- and dextran sodium
sulfate-induced colitis and chronic colitis in interleukin 10-negative (IL10 / ) mice. Aluminum increased the intensity
and duration of macroscopic and histologic inflammation, colonic myeloperoxidase activity, inflammatory cytokines
expression, anddecreased the epithelial cell renewal comparedwith control animals. Under basal conditions, aluminum
impaired intestinal barrier function. In vitro, aluminum induced granuloma formation and synergized with
lipopolysaccharide to stimulate inflammatory cytokines expression by epithelial cells. Deleterious effects of aluminum
on intestinal inflammation andmucosal repair strongly suggest that aluminummight bean environmental IBD risk factor.
INTRODUCTION
Inflammatory bowel diseases (IBDs), which include Crohn’s
disease and ulcerative colitis, are chronic diseases characterized
by an excessive uncontrolled intestinal inflammation resulting
from an abnormal immune response to commensal microbiota
in a susceptible host.1 In the past 10 years, genetic research in
IBD has been particularly fruitful. However, among the many
susceptibility genes identified (4100 to date) none were
demonstrated to be necessary or sufficient for disease onset.2,3
The spatial heterogeneity of Crohn’s disease and ulcerative
colitis, their increasing incidence and prevalence with time and
in different regions around the world, the low concordance rate
in monozygotic twins and the increased risk among migrants
from low-incidence to high-incidence areas are strong argu-
ments implying an important role for environmental factors in
the pathogenesis of IBD.4,5 However, besides smoking and
appendectomy and, more recently, exposure to antibiotics in
childhood, no strong environmental factors have been iden-
tified to date.6–9
The increase of IBD in developing countries has focused
attention on the potential role of industrialization and
environmental pollutants as causative environmental factors
in their pathophysiology.10,11 Twentieth century industrializa-
tion has led to an increased accumulation of heavy metals, and
in particular aluminum, in our surrounding ecosystems.
Aluminum is ubiquitous and is the most abundant metal
element in our environment.12,13 In the past 50 years, world-
wide production of aluminum has regularly increased, from
o5million tons in 1960 to425million tons in 2002, and deve-
loped countries have raised their current domestic consump-
tion by 350%.14,15 A main route of exposure to aluminum for
the general population is through food and water. The decline
in the use of unprocessed foods and the increased consumption
of cakes, pastries, and sugar-rich foods characterizing ‘food
1Univ Lille Nord de France, Lille, France. 2Inserm U995, Lille, France. 3UDSL, Lille, France. 4Hepato-Gastroenterology Department, CHU Lille, Lille, France. 5Division of
Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland. 6INSERM, UMR892, Nantes, France. 7CNRS, UMR6299, Nantes, France. 8Universite´ de
Nantes, Nantes, France. 9Clinical Bacteriology, College of Pharmacy, Lille, France. 10Finlay Lab, Michael Smith Laboratories, University of British Columbia, Vancouver,
British Columbia, Canada and 11Department of Immunology, St Jude Children’s Research Hospital, Memphis, Tennessee, USA. Correspondence: C Vignal
(cecile_vignal@hotmail.com)
12Shared first authorship.
Received 9 January 2013; revised 12 August 2013; accepted 14 August 2013; advance online publication 16 October 2013. doi:10.1038/mi.2013.78
nature publishing group ARTICLES
MucosalImmunology 1
westernization’ has resulted in an increased ingestion of
aluminum, which exceeds the tolerable weekly intake of
7mg kg 1 per week in a significant proportion of the European
and North American populations.16 For many years, exposure
to aluminum was suggested to favor an abnormal immune
response in different diseases, including autoimmune condi-
tions.17 However, despite this known toxicity and a potential
gut interaction, aluminum and its effect on intestinal home-
ostasis and inflammation have not been investigated so far,
particularly in the physiopathology of IBD.
The aim of our study was to explore the pro-inflammatory
role of aluminum in differentmodels of chemically induced and
chronic colitis in mice. Particular attention was paid to the
interaction between aluminum and epithelial cells and its role
in the immune response against bacteria.
RESULTS
Aluminumworsens colitis inducedby 2,4,6-trinitrobenzene
sulfonic acid and dextran sodium sulfate in mice
In a first set of experiments, C57BL6 mice were fed for 4 weeks
with aluminum citrate (AluCi) or aluminum phosphate (AluP)
at a concentration of 1.5mg Al element kg 1 per day. These
four weeks’ oral administration of aluminum did not induce
any macroscopic, histological, or molecular colonic inflamma-
tion (Supplementary Figure 1 online). In another set of
experiments, C57BL6mice were treated with AluCi or AluP for
4 weeks before rectal administration of 2,4,6-trinitrobenzene
sulfonic acid (TNBS; Figure 1a). Four days after colitis
induction, the severity of intestinal inflammation was asses-
sed by macroscopic, histological, and molecular parameters.
Macroscopic Wallace score of colonic inflammation was
significantly increased in both forms of aluminum-treated
mice compared with phosphate buffer saline (PBS)-treated
mice (Figure 1b). Aluminum-treated mice presented more
severe and extended macroscopic inflammation of the colon
with large areas of ulceration (data not shown). Consistently, at
the microscopic level, the histological Ameho score of colonic
inflammation was more severe in both forms of aluminum-
treated mice compared with PBS-treated mice, leading to more
extensive ulceration and necrosis involving 80% of the whole
colon (Figure 1c,d). Myeloperoxidase (MPO) activity reflect-
ing neutrophil infiltration was also significantly higher in
aluminum-treated mice compared with PBS-treated mice
(Figure 1e).
Figure 1 Aluminum worsens 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis. (a) C57BL6 mice (n¼ 14 per group) were fed with
aluminum citrate (AluCi) or aluminum phosphate (AluP) (1.5mg of Al element kg 1 per day) or with phosphate buffer saline (PBS) for 31 days. At day 28,
colitis was induced by intrarectal administration of TNBS. Four days after colitis induction, mice were euthanized and colitis parameters were
assessed. (b) The macroscopic Wallace score was determined as described in Methods. (c, d) Histopathological changes in colon tissues were
examined byMay-Gru¨nwald and Giemsa (MGG) staining and scoring was performed as described in Methods. (e) Myeloperoxidase (MPO) activity was
measured in colonic lesions. Results are expressed as the percentage of variation compared with TNBS-treated mice.
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To complete our understanding of the detrimental effect of
aluminum observed in TNBS-induced colitis, BALB/C mice
were concomitantly treated by aluminum gavage and oral
administration of dextran sodium sulfate (DSS) 2.5% in
drinking water for 7 days (Figures 2a and 3a). A 2-fold increa-
sed mortality was observed in AluCi-treated mice with DSS-
induced colitis compared with control animals (Figure 2b).
Moreover, mice treated with DSS and AluCi or AluP had more
than a 3- and 2-fold body weight loss, respectively, compared
with DSS and PBS-treated mice (Figures 2c and 3b). The body
weight loss occurred at the lowest aluminum concentration of
0.15mg kg 1 per day and was more pronounced with higher
doses such as 1.5 and 15mg kg 1 per day (Figure 3b). The
disease activity index (DAI), combining weight loss, stool
consistency, and the presence of rectal bleeding, was also
increased in both forms of aluminum-treated mice compared
with PBS-treated mice with colitis (Figures 2d and 3c). Consis-
tently, colonic MPO activity was increased in aluminum-
treated mice compared with control animals, with colitis
together with a more intense inflammatory infiltrate mainly
located in the mucosal and submucosal layers (Figure 2e,f). To
demonstrate that our results were specific to aluminum, mice
were fed with another metal, namely zinc phosphate (ZnP)
together with colitis induction (Figure 3a). Mice treated
with ZnP experienced the same body weight loss as DSS- and
PBS-treated mice and no difference in DAI was observed
(Figure 3b,c). As a whole, these results demonstrated that two
different forms of aluminum worsened lesions severity in two
distinct models of colitis in mice.
Aluminum worsens chronic colitis in interleukin
10-negative mice
We then investigated the effects of aluminum in a chronic
colitismodel. Interleukin 10-negative (IL10 / )mice received
AluCi in their drinking water for 7 weeks with a daily dose of
1.5mgAl element per kg bodyweight (Figure 4a).Macroscopic
mucosal damage was assessed by mini-endoscopy score
(Figure 4b,c). Mucosa from IL10 / mice receiving water
showed overt signs of inflammation. IL10 / mice treated
with AluCi had a mucosa less transparent, a vascular pattern
more altered, more fibrin and a significant increase in
mucosa granularity compared with IL10 / mice receiving
water. The histological score for IL10 / mice treated
with AluCi was significantly increased compared with the
water-treated IL10 / mice (Figure 4d,e). MPO activity was
significantly more elevated in AluCi-treated IL10 / mice
than in control IL10 / mice (Figure 4f). Taken together,
these data argued in favor of a worsening effect of
oral aluminum on the development of chronic colitis in
IL10 / mice.
Figure 2 Aluminum citrate (AluCi) worsens dextran sodium sulfate (DSS)-induced colitis. (a) BALB/C mice (n¼ 10 per group) were treated
with 2.5%DSSandAluCi (1.5mg of Al element kg 1 per day) or phosphate buffer saline (PBS) for 7 days. Controlmice treatedwith AluCi or PBSwithout
DSS were followed for the same period (n¼ 5 per group). (b) Survival of mice was monitored until day 7 after the start of DSS. (c) Body weight
was scored daily. * means Po0.05 between DSS±PBS and DSS±AluCi. (d) A disease activity index that included body weight variation,
the presence of blood in stools, and stool consistency was calculated at day 7. (e) Myeloperoxidase (MPO) activity was measured on colons
harvested at day 7. (f) Histopathological changes of colonic tissues were examined by May-Gru¨nwald and Giemsa (MGG) staining.
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Aluminum increases the inflammatory cytokine expression
in different models of colitis
AluCi significantly increased the expression of Il1b and Il17a
mRNA in the colon of animals 4 days after TNBS adminis-
tration (Figure 5a). The modification of this colonic cytokine
profile induced by aluminum gavage and TNBS administration
was associated with an increased expression of Nlrp3 mRNA
(Figure 5a), a known intracellular innate immune marker of
inflammasome response regulated by aluminum.18 Similar
data were obtained in animals with DSS-induced colitis, where
AluCi administration also significantly upregulated the colonic
expression of inflammatory cytokines and Nlrp3 mRNA
compared with untreated mice with colitis (Figure 5b).
Similar results were observed with AluP (data not shown).
In the chronic model of colitis, mucosal levels of Il1b, Il17a,
andNlrp3 tended to be higher in the IL10 / mice intoxicated
with AluCi compared with IL10 / mice receiving water
(Figure 5c).
Enhanced inflammatory cytokine expression in aluminum-
treated epithelial cells and potentiation by bacterial
components
To investigate the potential inflammatory effect of luminal
aluminum on the first intestinal layer in contact with luminal
antigens and particles, we incubated HT-29 and Caco-2
epithelial cells for 3 h with increased concentrations of
aluminum from 10 to 100 mg of Al element/ml 1. A dose-
response effect of aluminum was observed in Caco-2 cells,
leading to an increased expression of the inflammatory
cytokines IL8 and IL1b mRNA (Figure 6a). Similar data
were obtained with HT-29 epithelial cells (data not shown).
Co-incubation of Caco-2 cells with a low concentration of
bacterial lipopolysaccharide (LPS, 1 mgml 1) and increased
concentrations of aluminum led to a synergistic and dose-
dependent pro-inflammatory effect with an increased
expression of IL8 and IL1b mRNA (Figure 6b). Similar
data were obtained in HT-29 cells (data not shown).
Aluminum extends colitis duration and decreases the
mucosal healing
Besides its effects on colitis severity, we investigated the influ-
ence of oral administration of AluCi at 1.5mg Al element kg 1
on colitis duration inC57BL6mice submitted to one cycle of 2%
DSS for 7 days (Figure 7a). Colonic lesions were evaluated
during the 19-days experiment to investigate the persistence
of lesions during the recovery period. At the end of DSS
administration, mice treated with aluminum continued to
lose weight and presented a slow recovery compared to mice
with colitis receiving the vehicle (Figure 7b). In contrast,
body weight changes were paralleled after day 7 in control mice
with or without DSS-induced colitis receiving the vehicle and
control animals treated with aluminum (Figure 7b). At day 19,
animals with DSS-induced colitis receiving aluminum
presented persistent intestinal inflammation, as demon-
strated by an increase in DAI, colonic MPO activity and
histological lesions (Figure 7c–e). To confirm the deleterious
effect of aluminum on colitis healing, we designed a subsequent
experiment where aluminum was started just after DSS-
induced colitis (Figure 8a). In contrast to control animals,
which completely recovered their initial body weight 10 days
after DSS-induced colitis, administration of AluCi signifi-
cantly delayed weight gain and led to a sustained increase
in colonic weight/size ratio compared with control animals
(Figure 8b,c).
Figure 3 Aluminumphosphate (AluP) but not zinc phosphate (ZnP)worsens dextran sodiumsulfate (DSS)-induced colitis. (a) BALB/Cmice (n¼10per
group) were treated with 2.5% DSS and with increasing doses of AluP (0.15, 1.5, and 15mg of Al element kg 1 per day) or ZnP (1.5mg of
Zn element kg1 per day) or phosphate buffer saline (PBS) for 9 days. (b) Body weight was scored daily. * means Po0.05 between DSS±PBS
and DSS±AluP 1.5 and 15, y means Po0.05 between DSS±PBS and DSS±AluP 0.15. (c) A disease activity index that included body weight
variation, the presence of blood in stools, and stool consistency was calculated at day 9.
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To better evaluate the effects of aluminum on colonic
wound healing, we quantified ex vivo epithelial cell prolifera-
tion and apoptosis in the colon of C57BL6 mice receiving
or not receiving aluminum 10 days after DSS-induced colitis
(Figure 9a). AluCi administration was associated with an
inhibition of epithelial cell proliferation, as assessed by
proliferating cell nuclear antigen (PCNA) immunostaining,
compared with control animals (Figure 9a,b). The mean
fluorescence of terminal transferase dUTP nick end labeling
(TUNEL)-stained colon sections was similar in animals with
colitis receiving or not receiving aluminum (Figure 9c,d).
To confirm the direct influence of aluminum on epithelial
cell proliferation, we performed an explanatory experiment in
HT-29 cells.We showed that aluminum inhibited epithelial cell
proliferation by 440% without modification of cell death
assessed by lactate deshydrogenase release (Figure 9e,f).
Aluminum alters the intestinal barrier and induces
granuloma formation
Wenext assessed the intestinal effects of aluminumgiven once a
day (1.5mg kg 1) for 4 weeks on epithelial barrier integrity.
The rate of bacterial translocation, reflecting the intestinal
barrier, was very low in the mesenteric lymph nodes (MLN) of
control C57BL6 mice receiving PBS (Figure 10a). In contrast,
more than a 100-fold increased colonization of MLN was
observed in animals receiving AluP (Figure 10a). Tight
junctions of epithelial cells involving occludins, claudins,
and zonula occludens are critical to maintain intestinal barrier
function. A significant decrease in occludin (Ocln) mRNA
expression was observed in the colon of mice treated with
aluminum compared with PBS-treated control animals
(Figure 10b). We then evaluated the effect of aluminum on
colonic flora bulk and composition. Both remained similar in
the colon of mice receiving aluminum or PBS (Figure 10c).
Altogether, these data suggest that aluminum enhanced intes-
tinal permeability leading to an increased load of bacteria
through the intestinal wall without a concomitant increase in
bacterial pressure in the colon.
The number and size of granulomas developed in vitro was
evaluated after a 4-day incubation of human peripheral blood
mononuclear cells (PBMCs) from healthy donors with
increasing concentrations of AluP alone and/or together with
Mycobacterium bovis strain BCG (BCG), adherent/invasive
Escherichia coli strain LF82 (AIEC) and a non-pathogenic
Figure 4 Aluminum citrate (AluCi) aggravates chronic colitis in interleukin 10-negative (IL10 / ) mice. (a) Eight-week-old IL10 / mice were
treatedwith AluCi (1.5mg of Al element kg1 per day) in their drinkingwater (n¼ 15) or with water only (n¼14) for 49 days. (b) The five parameters of the
murine endoscopic index of colitis severity (MEICS) were determined. (c) Mini-endoscopic images were done as described in Methods. (d, e)
Histopathological changes in colon tissues were examined by May-Gru¨nwald and Giemsa (MGG) staining and scoring was performed as described in
Methods. (f) Myeloperoxidase (MPO) activity was measured in colonic lesions.
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Figure 5 Aluminum citrate (AluCi) increases the expression of pro-inflammatory cytokines in colitis. Il1b, Il17a, and Nlrp3 mRNA levels from
homogenized colons of (a) mice treated with 2,4,6-trinitrobenzene sulfonic acid (TNBS) and phosphate buffer saline (PBS) or treated with TNBS and
AluCi, (b)mice treatedwith dextran sodium sulfate (DSS) andPBS or treatedwith DSS andAluCi, and (c) interleukin 10-negative (IL10 / ) mice treated
or not with AluCi.
Figure 6 Aluminum phosphate (AluP) stimulates the expression of interleukin 8 (IL8) and IL1b by intestinal epithelial cells and enhances their
response to bacterial stimuli. (a) Caco-2 cells were incubatedwith increasingdoses of AluP (from10 to 100 mgof Al element ml 1). qPCRassay onCaco-
2 cell lysates showed a dose-dependent increase in IL8 and IL1b expression in the presence of aluminum. (b) Caco-2 cells were co-stimulated
with increasing doses of AluP (from 10 to 100 mgml1) and lipopolysaccharide (LPS). qPCR assay on Caco-2 cell lysates showed a dose-dependent
increase in IL8 and IL1b expression in the presence of aluminum compared with LPS stimulation alone. *Po0.05 vs. controls.
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Escherichia coli K-12 strain DH5a.19,20 As expected, no granu-
lomas were observed in control wells without aluminum and
bacteria. The granuloma count increased proportionally until
700 granuloma counts per well with the increased dose
of aluminum, with a positive effect beginning at a very
low concentration of aluminum (5 ng Al elementml 1)
Figure 7 Aluminum citrate (AluCi) extends the duration of dextran sodium sulfate (DSS)-induced colitis. (a) C57BL6 mice (n¼ 10–15 per group)
were treated with 2% DSS for 7 days, followed by regular drinking water for 12 days. In parallel, mice were treated with AluCi (1.5mg of Al element kg1
per day) or phosphate buffer saline (PBS) once a day until the end of the experiment. (b) Body weight was scored at baseline, D7, D13, D15,
and D19. * means Po0.05; ** means Po0.01 between DSS±PBS and DSS±AluCi. (c) A disease activity index that included body weight variation,
the presence of blood in stools, and stool consistencywas calculated at day 19. (d) Myeloperoxidase (MPO)wasmeasured in colonic samples harvested
on day 19. (e) Histopathological changes in the colon tissues were examined by May-Gru¨nwald and Giemsa (MGG) staining and scoring of
histopathology, as described in Methods.
Figure 8 Aluminum citrate (AluCi) decreases the mucosal repair. (a) C57BL6 mice were treated with 2% dextran sodium sulfate (DSS) for 7 days,
followed by regular drinking water for 10 days. AluCi (1.5mg of Al element kg 1 per day) and phosphate buffer saline (PBS) treatment were started only
after DSS discontinuation on day 7. (b) Body weight was scored daily. * means Po0.05. (c) Colon length and weight were measured from mice
euthanized on day 0, day 6, and day 10 after the start of aluminum treatment and the colon weight/size ratio was calculated.
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(Figure 10d,e). Same experiments were performed with Zn
and no granuloma formation was observed, showing a specific
effect of aluminum (data not shown). We then evaluated the
effect of a suboptimal concentration of aluminum (5 ngml 1)
on bacteria-induced granulomas. As previously described, non-
pathogenic E. coli, AIEC, and mycobacteria induced granu-
lomas formation, with a mean number per well of 101.5±24.5,
224.5±72.3, and 278.8±47.3, respectively.20 Aluminum at the
dosage of 5 ngml 1 potentiated the effect of bacterial infection
on granulomas formation, resulting in an increased number
and a bigger size of granulomas (Figure 10f).
Altogether, these data suggest that aluminum administration
leads to a leaky gut, enhancing intestinal bacterial translocation
and favoring development of granulomas.
DISCUSSION
Our study provides strong evidence that aluminum modulates
intestinal inflammation in vivo in mice. A daily intake of
aluminum at a concentration observed in the environment
increased the severity as well as the duration of intestinal
inflammationwith impairedmucosal repair in differentmodels
of colitis in mice. Aluminummediated intestinal inflammation
through several mechanisms, including inflammatory response
against bacteria, epithelial cell renewal and occludin expression,
which affected the intestinal barrier and favored granulomas
formation.
In humans, the principal route of entry of aluminum is the
ingestion of food or water containing aluminum.12,13 Oral
bioavailability of aluminum is estimated to be o1%.21
Aluminum accumulates in the skeletal system and the brain,
and a link with diseases such as osteomalacia and encepha-
lopathy, Alzheimer and Parkinson’s diseases have been
reported.16,22,23 The low percentage of oral bioavailability of
aluminum is actually misleading. In fact, after oral adminis-
tration, 40% of the ingested dose accumulates within the
intestinal mucosa, which makes the gut the main storage organ
for aluminum in the body.24,25 Intestinal accumulation of
aluminummay be particularly relevant to Crohn’s disease since
it has been identifiedwithinmacrophages of Peyer’s patches but
also around dilated submucosal lymphatics and in MLN.26–28
Figure 9 Aluminum citrate (AluCi) inhibits epithelial cell proliferation in vivo and in vitro. C57BL6 mice were fed with AluCi or phosphate buffer
saline (PBS) for 10 days after dextran sodium sulfate (DSS)-induced colitis. (a, b) Proliferating cell nuclear antigen (PCNA) immunostaining of
colon sections (a) and its quantification (b) showed a decrease in epithelial cell proliferation in mice having received aluminum as compared with mice
administered phosphate buffer saline (PBS). (c, d) Terminal transferase dUTP nick end labeling (TUNEL) immunostaining of the same colons (c) and its
quantification (d) shows no significant difference in epithelial cell apoptosis. Caco-2 cells were incubated with increasing doses of AluCi (50 and
100 mgml 1) for 5 days. (e) MTT assay showed a decrease in epithelial cell proliferation. (f) Lactate dehydrogenase (LDH) activity assay in the
supernatants did not reveal any significant variation.
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In spite of this, the potential toxic role of aluminum in the gut
has been poorly studied. Interestingly, a fatal outbreak of
granulomatous enteritis with many histological similarities
with Crohn’s disease was reported in a group of horses sharing a
common environment. In the evaluation of the cluster, an
unexpected finding was the presence of aluminum excess in
affected tissues.29 Our results are in agreement with a study
reported only in the abstract form, in which oral aluminum
increased histological scores in IL10 knockout mice.30 More-
over, using two different experimental models of chemically
induced colitis developed in mice with different genetic
backgrounds, we here demonstrated that small amounts of
two different forms of aluminum enhanced the intensity and
duration of intestinal inflammation, leading to an increased
mortality, increased body weight loss, more intense macro-
scopic and histological lesions, and enhancement of colonic
MPO activities.
Importantly, the dose (1.5mg kg 1) and the route of
aluminum administration used in this study are relevant to
human exposure. Indeed, it was estimated by a US food
additives survey that most Americans ingest from 0.01 to
1.4mg total aluminum per kg body weight per day. In the same
study, it was estimated that B5% of Americans ingested
495mg aluminum per day (41.36mg per kg body weight) as
additives in commercially processed foods and beverages.16
In Europe, it was also estimated that the tolerable intake of
aluminum is exceeded in a significant proportion of the
population, especially in children, who are more vulnerable to
toxic effects of pollutants than adults.31,32 Moreover, these
estimations did not take into account aluminum ingestion
through pharmaceuticals, which is estimated to account for
99% of the aluminum ingested by individuals consuming
aluminum-containing medications.33 Aluminum can be found
naturally in different forms, we thus choose to study an organic
soluble form (citrate) and a particular form (phosphate). Our
results demonstrated that both forms of aluminum worsened
colitis and delayed mucosal healing, excluding a form-based
effect.
The precise mechanisms involved in the detrimental effects
of aluminum on intestinal inflammation are unknown.
Aluminum has potential direct cytotoxic effects at high
concentrations but most of its biological mechanisms of action
Figure 10 Aluminum alters intestinal barrier integrity and induces granuloma formation. C57BL6 mice were fed with aluminum phosphate
(AluP) (1.5mg of Al element kg 1 per day, n¼ 9) or phosphate buffer saline (PBS) (n¼ 4) for 4 weeks. Bacterial counts in mesenteric lymph nodes
(MLN) and colon were determined after 4 weeks. (a) Bacterial counts in MLN were significantly higher in aluminum-treated mice than in PBS-treated
mice. (b) RT-qPCR assay of homogenized colons showed a decrease in Ocln mRNA in mice treated with aluminum as compared with PBS-treated
mice. (c) Bacterial count of specific strains in the colonic mucosa showed no difference between aluminum-treated and PBS-treated mice.
(d) Human peripheral blood mononuclear cells (PBMCs) were incubated for 4 days with increasing doses of AluP (from 1 to 100 mg of Al element per
well; 1.5ml medium per well). Quantitative analysis of the number of granulomas showed a dose-dependent enhancement of granuloma
number in response to aluminum. (e) Representative light microscopy pictures ( 10) of the culture wells after 4 days of reaction revealed large
multicellullar structures (granulomas) in the presence of aluminum. (f) Human PBMCs were incubated for 5 days with non-pathogenic E. coli
K-12 strain DH5a, AIEC strain LF82 or BCG, alone or in the presence of a low dose of aluminum (5 ng of Al element ml 1). The number of
granulomas according to their size (Index 1, small size, Index 2, big size) was counted. CFU, colony forming unit.
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have been described when looking at its adjuvant effect in
vaccines.34 In the latter case, aluminum-induced inflammation
involves the Nlrp3 inflammasome but also Nlrp3-independent
effects mediated through macrophages, B and T cells, resulting
in an enhanced antigen-specific T-cell response and an
increased production of inflammatory cytokines.35 In the
present study, no direct intestinal cytotoxic effect of aluminum
was detected in control animals fed for 1 month with small
amounts of aluminum, nor when epithelial cells were cultured
with high concentrations of aluminum reaching 0.1mgml 1.
Consistent with previous studies analyzing in the skin or the
lung the immunobiology of intradermal or inhaled aluminum,
oral exposure to aluminum activated Nlrp3 and potentiated the
expression of several inflammatory cytokines.36,37 Further-
more, evidence supporting a key role of epithelial cells in
aluminum-sustained intestinal inflammation was obtained
both in vitro and in vivo and was in line with a previous study
showing that aluminum decreased the transepithelial electrical
resistance of Caco-2 cells.34 Using two different HT-29 and
Caco-2 epithelial cell lines, aluminum, in a dose-dependent
manner and synergistically with bacterial LPS, enhanced the
production of inflammatory cytokines and decreased by440%
their ability to proliferate. The relevance of our in vitro data was
further highlighted by the demonstration that animals treated
with aluminum presented an impaired epithelial wound
healing, with sustained inflammation and an increased
bacterial translocation to MLNs. Another mechanism of action
of aluminum may be through its direct interaction with
bacterial flora. In our experiments, aluminum did not modify
the bacterial composition of the colonic flora of mice. It has
been hypothesized that aluminum, through metal chelating
systems, could gain access to microorganisms and then alter
their pathogenicity and ability to induce an exuberant
granulomatous response.38 We here demonstrated that alu-
minum was indeed capable of stimulating granulomas for-
mation, either alone or when associated with bacteria.
Translation of experimental evidence to human diseases
remains hazardous. Aluminum exposure has already been
implicated in a variety of chronic undetermined inflammatory
diseases, such as multiple sclerosis, myofasciitis, pulmonary
granulomatosis, and rheumatoid arthritis.39–42 Since most
people living in industrialized and emerging countries are
routinely and inevitably exposed to aluminum, future descrip-
tive, genetic, and epidemiological studies will be necessary to
clarify the mechanisms leading to aluminum susceptibility in
patients. An emerging concept suggests that dysfunction of
xenobiotic processing enzymes expression or activity in the
intestinal mucosa may be an important event in the initiation
and progression of IBD.43,44 Indeed, several studies have
identified an association between single-nucleotide poly-
morphism in genes involved in xenobiotics detoxification
and susceptibility to IBD.45,46 New research activities should
now develop standard protocols for measuring aluminum in
intestinal tissues of patients with IBD and controls, and analyze
these data according to the genetic profile of their detoxification
enzymes.
METHODS
Animals. Five- to eight-week-old C57BL6 and BALB/C male mice
were purchased from Janvier Laboratory (Le Genest-St-Isle, France).
Animals were maintained under specific pathogen-free conditions in
the animal facility at the Institut Pasteur de Lille. B6-IL10tm1Cgn
(IL10 / ) mice were bred in the animal facility of the University
Hospital of Zurich. Animals had access to standard tapwater and chow
diet ad libitum. All animal experiments were approved by the local
animal care program and were in accordance with the European
convention on research animal protection.
Aluminum treatment. Aluminum phosphate (AlH6O12P3; Sigma-
Aldrich, Saint-Quentin Fallavier, France) or aluminum citrate
(AlC6O7H5)was diluted in PBS (Lifetechnologies, Saint Aubin, France)
and administered once a day with a gavage needle at a concentration of
1.5mg Al element per kg body weight, an amount equivalent to the
high end of the total aluminum range ingested daily by humans living
in contemporary urban society.16 The duration of aluminum treat-
ment was dependent on the setting of each experiment and was
detailed in each figure. A dose-response experiment was performed
and AluP was given to mice at a concentration of 0.15, 1.5, and 15mg
Al element per kg body weight per day. Zinc phosphate (Zn3(PO4)2)
diluted in PBS was used as a control and was orally administered
to mice at a concentration of 1.5mg Zn element per kg body weight
per day. Stock solutions of aluminum salts or ZnP, adjusted to mice
weight, were prepared weekly. In all experiments, control mice
received PBS by gavage.
For experiments performed with IL10 / mice, AluCi was
diluted in their drinking water at a concentration of 0.015mg Al
elementml 1 to reach a daily exposure of 1.5mg Al element per kg
body weight.
Induction of TNBS and DSS colitis. TNBS colitis was induced in
anesthetized C57BL6 mice by intrarectal administration of TNBS
(150mg kg 1; Sigma-Aldrich) diluted in a 1:1 (v/v) mix of 0.9% NaCl
and 100% ethanol, as described previously.47 Control animals received
an NaCl/ethanol mix using the same technique. Mice were euthanized
4 days after TNBS/ethanol administration.
Acute colitis was induced with 2.5% (w/v) DSS (45 kDa; TdB
Consultancy, Uppsala, Sweden) dissolved in water for 7–9 days. For
recovery experiments, colitis was induced by feeding mice with 2%
(w/v) DSS for 7 days, followed by normal water until the end of the
experiments, 10 or 12 days after DSS discontinuation. At the end of
each experiment, mice were assessed for clinical score and euthanized.
Determination of clinical scores. For TNBS-induced colitis, animals
were euthanized and the colon of each mouse was dissected and cut
longitudinally to reveal the colonic mucosa. The intensity of colonic
lesions was first evaluated macroscopically according to the Wallace
score.48 TheWallace score rates macroscopic lesions on a scale from 0
to 10 based on features reflecting inflammation, such as hyperemia,
thickening of the bowel, and the extent of ulceration. A colon specimen
located within the ulceration was used for histological evaluation. The
other parts of the colon were frozen for subsequent analysis of mRNA
expression and MPO activity quantification.
For DSS-induced colitis, body weight was determined regularly
during DSS and the water administration phase until the end of each
experiment. At the end of each experiment, animals were assessed for
clinical score by recording body weight variation, stool consistency,
and occult blood before being euthanized. A DAI was determined as
previously described and is summarized in Supplementary Table 1
online.49 Rectal bleedingwas assessedwith theColoScreen III Lab Pack
(Elitech, Salon-de-Provence, France). The DAI score ranged from 0
(healthy) to 12 (greatest level of colitis). After euthanasia, the colonwas
carefully dissected and its weight and size were measured. Circular
sections of the colon were prepared for histological analysis. The other
parts of the colon were frozen for subsequent analysis of mRNA
expression and MPO activity quantification.
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In the model of chronic colitis, IL10 / animals were anesthetized
intraperitoneally with a mixture of 100mg ketamine (Ve´toquinol,
Bern, Swizerland) and 8mg of Xylazine (Bayer, Lyssach, Switzerland)
per kg body weight and examined as described previously with
the Tele Pack Pal 20043020 (Karl Storz Endoskope, Tuttloingen,
Germany).50 Colonoscopy was scored using the murine endo-
scopic index of colitis severity scoring systemas described previously.51
After euthanasia, circular sections of the colon were prepared for
histological analysis. The other parts of the colon were frozen for
subsequent analysis of mRNA expression and MPO activity
quantification.
Histology. Colons were fixed in 4% paraformaldehyde, and embedded
in paraffin (Labonord, Templemars, France). Tissue sections were
stained withMay-Gru¨nwald and Giemsa and evaluated blindly by two
investigators. Histological lesions of mice with TNBS-induced colitis
were quantified using the modification by Ameho of the histo-
pathological grading system ofMacpherson and Pfeiffer (ranging from
0 to 6).48 Briefly, histological findings identical to those of normalmice
were scored as 0, mild mucosal and/or submucosal inflammatory
infiltrate and edema, punctatemucosal erosions, and intactmuscularis
mucosaewere scored as 1, the same histological findings involving 50%
of the specimen were scored as 2, prominent inflammatory infiltrate
and edema, deeper areas of ulceration extending through the mus-
cularis mucosae into the submucosa, and rare inflammatory cells
invading the muscularis propria but without muscle necrosis were
scored as 3, the same histological findings involving 50% of the
specimen were scored as 4, extensive ulceration with coagulative
necrosis with deep extension of the necrosis into the muscularis
propria were scored as 5, and the same histological findings involving
50% of the specimen were scored as 6.
ForDSS-induced colitis and chronic colitis, histological lesions were
assessed using a score quantifying the intensity of the inflammatory
cell infiltrate (scores 0–3) and the tissue damage (scores 0–3) as
previously described.49 Briefly, the presence of occasional inflamma-
tory cells in the lamina propria was scored as 0, increased numbers
of inflammatory cells in the lamina propria as 1, confluence of
inflammatory cells extending into the submucosa as 2, and transmural
extension of the infiltrate as 3. For tissue damage, scores were 0, no
mucosal damage; 1, lymphoepithelial lesions; 2, surface mucosal
erosion or focal ulceration; 3, extensivemucosal damage and extension
into deeper structures of the bowel wall. The combined histological
score ranged from 0 (no changes) to 6 (extensive infiltration and tissue
damage).
MPO activity measurement. MPO activity was measured to monitor
the degree of neutrophil infiltration in the colonic lesions during
chemically induced and chronic colitis.52 Colon specimens were
homogenizedwith anUltra Turrax T8 (Ika-Werke, Staufen, Germany)
in a phosphate buffer (pH 6.0) containing 0.5% hexadecyltrimethyl
ammonium and subjected to two sonication and freeze-thaw
cycles. The suspensions were centrifuged at 14,000 g for 15min at
4 1C and the supernatants were reacted with 1mgml 1 o-dianisidine
hydrochloride and 0.0005% hydrogen peroxide. The optical density of
each sample was read at 450 nm with a Versamax microplate reader
(MDS Analytical Technologies, Saint-Gre´goire, France). One unit of
MPO activity was defined as the amount that degraded 1 mmol pero-
xidase per minute at 25 1C. The results were expressed as absorbance
per total quantity of proteins determined by the Bradford method.
PCNA staining and TUNEL. Ex vivo cell proliferation was assessed by
staining for PCNA. Colonic sections were boiled in 0.1 M sodium
citrate buffer pH 6.0 for 6min for antigen unmasking. After washing,
sections were blocked for 30min with 5% bovine serum albumin in
PBS, stained overnight at 4 1C with anti-PCNA antibody (1/50)
(Santa Cruz Biotechnology, Dallas, TX), and incubated with Alexa 488
conjugated secondary antibody (1/100) (Invitrogen, Saint-Aubin,
France) for 1 h. Sections were counterstained with DAPI (Molecular
Probes, Eugene, OR). To ensure specificity of immunostaining, con-
trol sections underwent simultaneous staining with isotype control
antibody.
Detection of apoptosis was performed by TUNEL assay using the
in situ cell death detection kit (Roche, Meylan, France). Sections were
permeabilized with 1%Triton X-100, 0.1% sodium citrate, washed and
stained for TUNEL according to the manufacturer’s instructions.
Sections were counterstained with DAPI.
The quantification of positive TUNEL- or PCNA-stained cells was
performed randomly using the ImageJ processing and analysis software
(NIH, Bethesda, MD). Images were acquired with a DM5500B
microscope equippedwith aDFC 310 FX camera (LeicaMicrosystems,
Nanterre, France) and mucosal layers were photographed at a
magnification of  10 to measure specific fluorescence intensity.
Cell line stimulation assay. Caco-2 and HT-29 epithelial cells were
cultured in 12-well plates (density of 5 105 cells per well) with
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal
bovine serum (Eurobio, Courtaboeuf Cedex, France) and 1% peni-
cillin-streptomycin (Invitrogen), at 37 1C in 5% CO2/95% humidified
air. Cellswere treatedwithAluP at different concentrations (10–100 mg
Al elementml 1) with or without LPS (1mgml 1; Sigma-Aldrich) for
3–6 h. After the incubation period, cells were washed twice with sterile
PBS, then lysed with RA1 buffer containing 1% b-mercaptoethanol
(Macherey-Nagel, Du¨ren, Germany).
For the determination of cytotoxicity and proliferation, cells
were incubated with aluminum for 5 days. Supernatants were
collected for lactate deshydrogenase measurement (Cytotoxicity
detection kit; Roche) and cell proliferation was assessed using
a colorimetric MTT cell proliferation assay (Interchim, Montluc¸on
Cedex, France). Optical density was read at 500 and 570 nm,
respectively, with a Versamax microplate reader (MDS Analytical
Technologies).
RNA extraction and real-time qPCR. Total RNA was extracted from
colonic samples with the NucleoSpin RNAII commercial kit
(Macherey-Nagel), as described by the manufacturer. cDNA was
preparedwith theHighCapacity cDNAArchive kit andRT–qPCRwas
performed with SyBrGreen (Applied Biosystems, Saint-Aubin,
France). Beta-actin was used as a reference gene and primer sequences
are listed in Supplementary Table 2.
Microbiologic analysis. Colon samples and MLN were introduced
into pre-weighed vials containing 1.5ml of cysteinated Ringer’s
solution. After physical disruption of the colon specimens, 10-fold
dilutions were performed in the same diluent (decimal dilutions from
10–2 to 10–5). Each dilution was spread onto plates of non-selective
blood agar (modified Columbia agar) incubated at 37 1C for 1 week
under anaerobic conditions, McConkey plates (BioMerieux, Marcy
l’Etoile, France) incubated at 37 1C for 48 h under aerobic conditions,
andMan, Rogosa, Sharpe plates incubated at 37 1C for 48 h underCO2-
enriched conditions. Total counts were performed, and different types
of colonies were subcultured and identified following established
morphological and biochemical criteria. Quantitative results are
expressed in log colony forming unit(CFU) g 1. The threshold of
detection is 104 CFU g 1.
After disruption ofMLN in the Ringer’s solution, 1ml was grown in
brain-heart enrichment broth and 0.1ml was spread onto plates of
non-selective blood agar and incubated at 37 1C for 1 week under
anaerobic conditions. If the brain-heart enrichment broth became
turbid, then 0.1ml was spread onto plate of non-selective blood agar
and incubated at 37 1C for 1 week under anaerobic conditions. Sub-
cultured bacteria were identified as above. The threshold of detection
was 102 CFU g 1. All samples were analyzed in a blind manner.
In vitro granulomas formation. Fresh human blood from healthy
volunteers was obtained from the Etablissement Franc¸ais du Sang and
was diluted 1/1 (v/v) with RPMI (Invitrogen), layered gently onto a
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ficoll-paque solution (Amersham, Courtaboeuf Cedex, France) and
then centrifuged for 40min at 1,800 r.p.m. PBMCs were collected and
washed three times in RPMI medium by 10min centrifugation at
1,800 r.p.m. Cells were counted with a Malassez cell and diluted to a
concentration of 1 106 cellsml 1 in RPMI media supplemented
with 7.5% heat-inactivated human AB serum (Sigma-Aldrich).
PBMCs were then incubated in 24-well plates with increasing con-
centrations of AluP or alone for 4–7 days, at 37 1C in a 5% CO2
atmosphere. In each well, the number of granulomas was counted.
Granulomas enumeration was performed using an inverted micro-
scope and a  4 objective (Olympus CK40, Olympus, Rungis, France).
Pictures were taken using an inverted microscope with a  4,  10,
or  40 objective (Nikon TE300 Eclipse, Champigny-sur-Marne,
France). For experiments with bacterial stimulation, PBMCs were
incubated with 1 103 non-pathogenic E. coli K-12 strain DH5a,
AIEC strain LF82 or 1 104 BCG, alone or with AluP (5 ng Al
elementml 1) for 4 days at 37 1C in a 5% CO2 atmosphere.
Granulomas enumeration was performed as previously described.
Results are represented as the total number of granulomas per well
and the percentage of small size (index 1) and big size granulomas
(indexes 2–4).
Statistical analysis. Data are presented as the mean±s.e.m.
Comparison between different treatment groups for quantitative
variables was performed using the Wilcoxon–Mann–Whitney test.
Two-tailed significance tests were used. Kaplan–Meier analysis
with log-rank statistics was performed in survival during DSS-
induced colitis. A P-value of o0.05 was considered as statistically
significant.
SUPPLEMENTARYMATERIAL is linked to the online version of the paper
at http://www.nature.com/mi
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